{"database":"ENA","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Fastqsanger.gz":["ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR676/006/SRR6762746/SRR6762746_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR676/007/SRR6762747/SRR6762747_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR676/007/SRR6762747/SRR6762747_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR676/006/SRR6762746/SRR6762746_2.fastq.gz"]},"type":"primary"},"statusCodeValue":200,"statusCode":"OK"}],"scores":null,"additional":{"omics_type":["Genomics"],"center_name":["City University of Hong Kong"],"full_dataset_link":["https://www.ebi.ac.uk/ena/browser/view/PRJNA433779"],"long_description":["Cas9 mRNA and sgRNA against miR125 are delivered to cancer cells by RBCEVs. After treatments, the genomic DNA of cancer cells are extracted and sent for Amplicon sequencing."],"tag":["xref:EuropePMC:PMC6004015"],"repository":["ENA"],"additional_accession":[]},"is_claimable":false,"name":"","description":"Cas9 delivered by RBCEVs against miR125","dates":{"last_updated":"2023-05-19","first_public":"2022-01-05"},"accession":"PRJNA433779","cross_references":{}}